PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
October 23, 2025Cancers0 citationsOpen Access

Evaluating Carbon Ion Radiotherapy for Unresectable Retroperitoneal Sarcoma

Carbon Ion Radiotherapy for Retroperitoneal Sarcoma: A Single-Institution Study

View Full Paper
Ask AI
Bookmark
Share

Authors

RIReiko ImaiTYTSUKASA YONEMOTONANobuhito Araki

Discussion

Loading...

Member takes

Overview

Retrospective analysis demonstrates overall survival rates of 68.3% at 3 years in patients with unresectable sarcoma, suggesting the need for multicenter studies.

Key Points

  • CIRT significantly improved overall survival rates in patients with unresectable retroperitoneal sarcoma, evidenced by survival rates of 68.3% and 49.4% at 3 and 5 years respectively.
  • Among treatment-naïve patients, abdominal recurrence-free survival rates after carbon ion therapy were 51.1% at 3 years and 29.1% at 5 years.
  • Utilizing a relative biological effectiveness dose of 70.4 Gy delivered over 16 fractions, patients exhibited a median overall survival time of 58.1 months.
  • CIRT presents a promising option but further multicenter studies are necessary to validate its effectiveness across broader patient populations.

Cite This Study

Imai et al. (2025) studied this question.

synapsesocial.com/papers/68f9f86eb2c35e10cc4e3db3https://doi.org/10.3390/cancers17203395
View Full Paper
Ask AI
Bookmark
Share